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Vaccinia protein VP39 has two RNA modifying activities. In monomeric form, it acts as an mRNA cap-specific 29-O-
methyltransferase, specifically modifying the ribose moiety of the first transcribed nucleotide of m7G-capped mRNA. In
association with VP55, the catalytic subunit of the vaccinia poly(A) polymerase, VP39 facilitates the rapid elongation of poly(A)
tails that are already greater than ;35 nt in length. Introducing new assays, we provide evidence that substrates for each
of VP39’s two activities do not detectably modulate the converse reaction and that VP39’s 29-O-methyltransferase activity is
not significantly affected by its association with VP55. In an electrophoretic mobility shift assay, VP39 interacted with a short
(5 nucleotide) RNA only when the latter was m7G-capped. Complexes with longer (22 nucleotide) RNAs were more stable (i.e.,
cap-independent) but were further stabilized by the presence of an m7G cap. An additional complex was observed at elevated
RNA:protein molar ratios, indicating the presence of two RNA binding sites per VP39 molecule. Interaction at one of these
sites was stabilized by the cap structure. Additional experiments indicated that RNA molecules undergoing poly(A) tail
elongation by the VP55-VP39 heterodimer are not favored as cap-methylation substrates. © 1998 Academic Press
INTRODUCTION
Vaccinia virus provides a model system for studies of
poxvirus replication. The virus encodes, and carries
within its virion, functional counterparts of transcription
and RNA modification machineries normally confined to
the host cell nucleus. These counterparts include en-
zymes for the attachment of eukaryotic-like m7G cap and
poly(A) tail structures to the 59 and 39 ends, respectively,
of nascent vaccinia transcripts (Gershon, 1997). The
mRNA cap 0 structure (m7G(59)pppN) and poly(A) tail are
added through the actions of the heterodimeric vaccinia
capping enzyme (Shuman, 1995) and VP55-VP39 (poly(A)
polymerase) heterodimer (Gershon et al., 1991; Moss et
al., 1975), respectively. Within the latter enzyme, adenyl-
ate addition is catalyzed solely by the VP55 subunit
(Gershon et al., 1991). However, VP55 can catalyze the
rapid and processive synthesis of tails no more than
30–35 nt in length, with longer tails being synthesized in
only a very slow and nonprocessive manner (Gershon
and Moss, 1992). The rapid and processive synthesis of
longer (physiological-length) tails requires the presence
of the VP39 subunit. The latter acts as a ‘‘processivity
factor’’ for VP55, enabling the VP55-VP39 heterodimer to
remain stably associated with poly(A) tails greater than
35 nt in length during their rapid elongation (Gershon
and Moss, 1993a). VP39 has a second, entirely unrelated
function, namely conversion of the mRNA 59 cap 0 struc-
ture to its cap I counterpart (m7G(59)pppNm) by methyl-
ation of the ribose moiety of the first transcribed nucle-
otide of the mRNA (Schnierle et al., 1992).
It is unclear whether VP39’s unusual bifunctionality
has arisen to facilitate some form of communication
between its two mRNA modifying functions. Here, we
have explored potential interactions between VP39’s two
functions. First, we have screened for the effects of
cap-specific 29-O-methyltransferase substrates upon
poly(A) tail elongation and vice versa. Second, although
association with VP55 is implicit in VP39’s action as a
polyadenylation processivity factor (Gershon and Moss,
1993a), the possible effects of VP55 upon VP39’s 29-O-
methyltransferase function have not been fully explored.
We have therefore screened for such effects and also for
the concurrent modification of both RNA ends by individ-
ual VP55-VP39 heterodimer molecules. Finally, in an ef-
fort to detect multiple RNA binding sites per VP39 mol-
ecule, we have adapted the electrophoretic mobility shift
assay (EMSA) for analysis of VP39–RNA interactions.
RESULTS
VP39 29-O-methyltransferase substrates/products do
not affect poly(A) tail elongation by the VP55-VP39
heterodimer
VP39 is a bifunctional protein which acts as both a
cap-specific 29-O-methyltransferase and a poly(A) poly-
merase (PAP) processivity factor (Gershon et al., 1991;
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Gershon and Moss, 1993a; Schnierle et al., 1992).
Whereas monomeric VP39 is active in cap methylation,
VP39 acts in poly(A) tail formation only in association
with VP55, the PAP catalytic subunit (Gershon et al.,
1991). We set out to investigate possible effects of 29-O-
methyltransferase substrates and products upon the
polyadenylation reaction. To this end, in vitro polyadenyl-
ation timecourse assays were conducted using either
59-monophosphate-terminated (Figs. 1A and 1B) or 59-
cap 0-terminated (Figs. 1C and 1D) versions of the VGF
60mer RNA as the polyadenylation substrate, only the
latter version is a substrate for cap-specific 29-O-meth-
ylation by VP39. For each polyadenylation substrate,
polyadenylation reactions were conducted in the pres-
ence of various concentrations of either S-adenosyl-L-
methionine (AdoMet) (Figs. 1A and 1C) or S-adenosyl-L-
homocysteine (AdoHcy) (Figs. 1B and 1D), the 29-O-meth-
yltransferase cofactor and corresponding coproduct,
respectively. For each of the four combinations of sub-
strate 1 cofactor/coproduct, increasing amounts of co-
FIG. 1. 29-O-methyltransferase substrate and cofactor/coproduct do not affect VP39’s poly(A) tail elongatory activity in vitro. (A and B) 32P-kinase-
labeled, uncapped VGF 60mer RNA substrate. (C and D) 32P-cap 0-labeled VGF 60mer RNA substrate. (A and C) Assays conducted in the presence
of various concentrations of AdoMet; (B and D) assays conducted in the presence of various concentrations of AdoHcy. The gel shown in each panel
has an equivalent layout, in which the first lane (R, showing labeled RNA alone), is followed by four polyadenylation timecourse assays. Each assay
contains VP55, the PAP catalytic subunit, and each except the first (2) also contains VP39. Numbers below each VP39-containing assay (0, 0.1, 1.0,
10) represent the concentration of AdoMet or AdoHcy (mM) present. For each assay, three lanes are shown, containing samples taken 30, 90, and
300 s after assay initiation. Standard assay conditions were employed (Materials and Methods), with reaction mixtures also containing NaCl (60 mM).
Reaction products were electrophoresed in standard 8% polyacrylamide, urea–TBE gels. The faint horizontal ‘‘line’’ running ;one-quarter the way
down the gels shown in parts (C) and (D) is an artifact of electrophoresis.
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factor/coproduct did not significantly affect rates of RNA
substrate utilization or product elongation or the lengths
of tail obtained. The slightly longer tails noticeable for the
capped than the uncapped RNAs (comparing Figs. 1C
and 1D with 1A and 1B, respectively) in the presence of
VP39 can be attributed to a greater protein:RNA ratio,
due to the use of lower concentrations of capped than
uncapped RNA in the assays. In Fig. 1B, the slightly
reduced tail lengths observed in the presence of 10 mM
AdoHcy correspond with the reduction of pH in this
assay from 9.0 to ;7.5 due to the acidity of the AdoHcy
stock solution. In Fig. 1C, conditions are appropriate for
simultaneous polyadenylation and 29-O-methylation of
the substrate.
To generate the 32P-cap 0-labeled RNA substrate used
for the experiments of Figs. 1C and 1D, the vaccinia
capping enzyme must catalyze a guanylation (32P-la-
beled GMP transfer) reaction followed by guanine N7-
methylation. Only the guanine-7-methylated (i.e., cap
0-terminated) form of the RNA is a bona fide substrate for
29-O-methylation by VP39 (Barbosa and Moss, 1978).
However, complete N7-methylation of the substrate’s
newly added guanine was not ensured, since the pres-
ence of the N7-methyl group would not have been de-
tectable by polyacrylamide gel electrophoresis of the
32P-labeled 60mer RNA product. A more rigorously de-
fined substrate was therefore tested. This comprised cap
0-terminated VGF 60mer RNA that was [3H]methyl la-
beled at the N7 position of the terminal guanine. The new
substrate was compared with an uncapped (59 32P-
monophosphate-terminated) version of the VGF 60mer,
as a polyadenylation substrate, in in vitro polyadenyla-
tion competition assays (Fig. 2). In these assays, either
32P- or 3H-labeled VGF 60mer RNA was mixed with 1-, 3-,
or 10-fold excess amounts of an identical, unlabeled
competitor RNA possessing a 59-terminal OH group, and
the mixtures were polyadenylated in the presence of
VP55, VP55 1 VP39, or VP55 1 VP39 1 unlabeled
AdoMet (Figs. 2A and 2B). The 59 OH-terminated RNA
competed effectively for utilization of the 32P-labeled
RNA substrate in the presence or absence of VP39 (Fig.
2A), indicating, as would be expected, that the 59 phos-
phate does not provide an advantage to the polyadenyl-
ation substrate. An equivalent result was obtained in the
equivalent experiment with 3H-labeled RNA substrate
(Fig. 2B), indicating that a 59 cap 0 structure confers
neither an advantage nor a disadvantage over a 59-
monophosphate or a 59-OH in the polyadenylation reac-
tion. Conditions favoring cap I formation by VP39 (i.e.,
cap 0-terminated substrate in the presence of VP55 1
VP39 1 AdoMet, Fig. 2B) did not appear to affect the
polyadenylation reaction, consistent with the lack of ef-
fect observed in Fig. 1C.
Separate studies (Lockless et al., 1998) indicate that
the minimum RNA chain length for cap methylation is two
or three transcribed nucleotides. Chromatographically
purified uncapped and m7G-capped RNAs close to the
minimum length (i.e., pppG(A)4 and m
7GpppG(A)4) were
tested as unlabeled competitors for the polyadenylation
of a 32P-labeled version of a polyadenylation-elongation
substrate, A50, by the VP55-VP39 heterodimer. In molar
excess amounts of up to 1003, neither pppG(A)4 nor
m7GpppG(A)4 competed detectably for the polyadenyla-
tion of 32P-A50 (Fig. 2C), despite m
7GpppG(A)4 being a
29-O-methyltransferase substrate. This indicated that
VP39 might possess distinct RNA-binding sites for its
two functions.
Substrates for poly(A) tail elongation by the VP55-
VP39 heterodimer do not affect the cap-specific
29-O-methyltransferase activity of VP39
The above experiments indicated that the polyadenyl-
ation activity of the vaccinia PAP heterodimer is not
influenced by substrates for or products of the VP39
cap-specific 29-O-methyltransferase reaction. In order to
assess whether VP39’s 29-O-methyltransferase activity is
influenced by an RNA substrate for poly(A) tail elongation
by the heterodimer, namely an oligoadenylated RNA,
oligoadenylated and nonoligoadenylated versions of an
unlabeled, 59 cap 0-terminated RNA (the VGF 60mer
RNA) were allowed to compete with one another for
29-O-methylation. To generate the necessary substrates,
a sample of unlabeled, cap 0-terminated VGF 60mer RNA
was divided into two equal portions, and one of these
was appended with a ;35-nt oligo(A) tail. The oligoad-
enylated and nonoligoadenylated species were then
mixed in equimolar amounts and included in an electro-
phoretic timecourse assay for 29-O-methyltransferase
activity in . fivefold molar excess over VP39, along with
[3H]AdoMet. RNA products were sampled at various
times after the start of the reaction, and the appearance
of [3H]RNA was monitored by gel electrophoresis and
fluorography. The oligoadenylated and nonoligoadeny-
lated RNA species became 29-O-methylated at compa-
rable rates (Fig. 3A). We therefore conclude that a sub-
strate for VP39’s tail elongatory activity (i.e. an oligo(A)
tailed RNA) does not significantly influence VP39’s activ-
ity in methylating the RNA 59 cap 0 structure. An addi-
tional experiment (Fig. 3B) showed that VP39’s 29-O-
methyltransferase activity was not significantly affected
by the presence of Mg:ATP, the small-molecule substrate
for the polyadenylation reaction.
Association with VP55 does not significantly influence
the methyltransferase activity of VP39
The experiments of Figs. 1–3 established that VP39’s
cap-specific 29-O-methyltransferase activity is not af-
fected by substrates for poly(A) tail elongation, and
poly(A) tail elongatory activity is not affected by sub-
strates for 59 cap methylation. Possible explanations
include: (i) monomeric VP39 targets the mRNA 59 cap
structure exclusively (presumably via its cap-enhanced
RNA binding activity (Shi et al., 1996)), whereas the VP55-
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VP39 heterodimer (the active species in polyadenylation)
targets only the mRNA 39 end, rendering it incapable of
59 cap methylation; and (ii) separate, noninterfering RNA
binding sites of VP39 are utilized for the protein’s poly-
adenylation and 29-O-methyltransferase activities. The
first possibility was addressed by determining whether
VP55 switches the specificity of VP39, converting it from
a 59 end to a 39 end modifying protein. This was done by
conducting 29-O-methyltransferase timecourse assays
similar to that shown in Fig. 3A, only in the absence and
presence of excess amounts of VP55. To control for
potential inhibitors that might have been introduced into
the assay along with VP55, a dimerization-defective VP39
mutant, CF3c2 (Shi et al., 1997), was also tested in the
absence and presence of VP55. CF3c2 has previously
FIG. 2. The 59 cap 0 structure does not affect VP39’s poly(A) tail elongatory
activity in vitro. (A) Control assays, showing polyadenylation of 59 32P-labeled
VGF 60mer RNA in the presence of excess unlabeled 59 OH-terminated VGF
60mer RNA competitor. Polyadenylation reactions were conducted in the
presence of vaccinia-expressed VP55 alone (55), VP55 1 vaccinia-expressed
VP39 (55 1 39), or VP55 1 VP39 1 unlabeled AdoMet (50 mM) (55 1 39 1
AdoMet). For each of these combinations, 0 refers to an assay conducted in
the absence of competitor; 3 and 10 refer to assays conducted in the presence
of 3- and 10-fold excess amounts, respectively, of unlabeled competitor. For
each assay, timepoints were taken 30, 90, and 300 s after assay initiation. R
refers to RNA alone. (B) Polyadenylation of 59 cap 0-labeled VGF 60mer RNA
in the presence of excess unlabeled 59 OH-terminated RNA competitor. The
3H label was incorporated at the 7-methyl position of the terminal guanine of
the cap, to ensure that all of the labeled substrate molecules possessed an
authentic cap 0 structure (see text). Other details are as for (A). (C) Testing
pppG(A)4 and m
7GpppG(A)4 as competitors in the poly(A) tail elongation
reaction, using 59 kinase-labeled A50 as the polyadenylation substrate. 2
denotes an assay conducted in the absence of competitor. 10, 30, and 100
indicate the fold excess of competitor. For each assay, timepoints were taken
30, 90, and 300 s after assay initiation. Other details are as for (A).
FIG. 3. Polyadenylation substrates do not affect VP39’s 29-O-methyl-
transferase activity. (A) Methylation timecourse assay, showing that
polyadenylated and nonpolyadenylated versions of the cap 0-termi-
nated VGF 60mer RNA are 29-O-methylated at equivalent rates. The
fluorographed gel shows the appearance of 3H-labeled RNA (i.e., 29-
O-methyltransferase product) in a timecourse reaction containing two
versions of the cap 0-terminated VGF 60mer RNA substrate: nonoli-
goadenylated (VGF 60) and oligoadenylated with a ;35-nt oligo(A) tail
(VGF 60-(A)35). Prior to the reaction, the two RNAs were mixed in
equimolar amounts. Samples were taken at various times (given above
each lane of the gel in min) after the addition of VP39 and [3H]AdoMet.
The dark blemish over the 4.5-min/VGF60-(A)35 band is from the X-ray
film. (B) Mg.ATP does not significantly affect the 29-O-methyltransferase
reaction. The standard methyltransferase assay (Barbosa and Moss,
1978) was performed in the absence and presence of 1 mM Mg.ATP. In
this experiment, E. coli-expressed GST-VP39 fusion protein was as-
sayed while anchored to glutathione beads. Anchored GST fragment
was used as a negative control.
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been shown to possess wild-type levels of 29-O-methyl-
transferase activity (Shi et al., 1997), and no defects have
been detected other than an inability to associate with
VP55. The 29-O-methylation substrate comprised a
nested ladder of capped RNAs generated by transcrip-
tion of a template for the RNA G(A)5 in the presence of
m7GpppG cap dinucleotide (Lockless et al., 1998). Assay
results (Fig. 4) indicated that products accumulate with
time in either the absence or the presence of a ;2.8-fold
molar excess of VP55, for both wild-type VP39 and mu-
tant CF3c2. Although the wild-type protein appears to
have lost a very small amount of activity in the presence
of VP55, no loss of activity was observed in other (repli-
cate) experiments, including those in which the VP55:
VP39 molar ratio was increased further (data not shown).
Furthermore, separate experiments have shown that
wild-type VP39’s KM for RNA substrate remains un-
changed in the presence or absence of excess molar
amounts of VP55 (H-T. Cheng and P. D. Gershon, unpub-
lished data).
Cap-dependent interaction of short capped
RNAs with VP39
Since VP39’s cap-specific 29-O-methyltransferase ac-
tivity is apparently not affected by its association with
VP55 (Fig. 4), the VP55-VP39 heterodimer can apparently
act at both RNA ends. One possibility is that it interacts
with the two RNA ends sequentially, i.e., via a single RNA
binding site. This seems unlikely, since 29-O-methyltrans-
ferase (capped) substrates do not interfere with polyad-
enylation and vice versa (Figs. 1–3). Furthermore, the
heterodimer would need to interact with mRNA 39 ends
efficiently despite VP39’s demonstrable targeting activity
for capped 59 ends (Shi et al., 1996). A second possibility
is that the heterodimer can interact with both ends si-
multaneously, i.e., via separate RNA binding sites. This
possibility is explored below.
Initially, an EMSA was developed to detect VP39–RNA
interaction. Highly purified VP39-DC26 (a 26-aa C-terminal
VP39 truncation mutant whose properties are indistinguish-
able from those of wild-type VP39 (Schnierle et al., 1994))
was used, along with capped and uncapped versions of a
highly purified short RNA, G(A)4. Since the capped version
is almost a minimum-length 29-O-methyltransferase sub-
strate (Lockless et al., 1998), EMSA complexes should pos-
sess only the minimum number of protein–RNA contacts
necessary for 29-O-methylation to occur. Whereas un-
capped (59 kinase-labeled) G(A)4 probe did not form a
detectable complex with VP39-DC26 in the EMSA (Fig. 5A),
a diffuse complex was observed with the cap-labeled ver-
sion, whose mobility was slightly lower than that of the free
RNA (Fig. 5B). Moreover, whereas the complex was com-
pletely stable in the presence of at least 70-fold molar
excess amounts of uncapped, unlabeled pppG(A)4 RNA
(Fig. 5B, left), equivalent amounts of the capped version
(m7GpppG(A)4) completely inhibited complex formation
FIG. 4. VP55 does not significantly influence VP39’s 29-O-methyltransferase activity. A 25% polyacrylamide gel shows the appearance of 3H-labeled
RNA (i.e., 29-O-methyltransferase product) with time. Timepoints (1, 2, 3, 4) were taken 15, 40, 120, and 300 s, respectively, after assay initiation.
Wild-type VP39 (wild-type) and a mutant whose only known lesion is an inability to associate with VP55 (CF3c2), were overexpressed in E. coli and
purified as described under Materials and Methods. Assays were conducted in the absence (2) and presence (1) of 2.8-fold molar excess amounts
of purified, baculovirus-expressed VP55. Amounts of VP39 and VP55 added to the assays had been accurately determined by quantitation of
Coomassie-stained gels as described (Shi et al., 1996).
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(Fig. 5B, right). The inactivity of smaller excess amounts of
the capped competitor (e.g., sevenfold) was likely due to the
molar excess of protein over RNA in the assay. These data
strongly indicated that VP39 can interact with the short RNA
G(A)4 in a cap 0-dependent manner. Confirmation that the
EMSA complex was cap 0-dependent came from an EMSA
experiment employing mutants with alanine substitutions in
m7G-contact residues (Hodel et al., 1997), namely mutants
Y22A, D182A, F180A, E233A, and a double mutant in which
both D182 and E233 had been converted to alanine. Mu-
tants Y22A, F180A, E233A, and the double mutant, each of
which had previously been shown to exhibit a loss of cap
0-dependent RNA binding enhancement in a BIAcore-
based assay for capped RNA–VP39 interaction (Hodel et
al., 1997; Shi et al., 1996), were also defective in the EMSA
(Fig. 5C). Mutant D182A, which showed wild-type levels of
cap-enhanced RNA binding in the BIAcore assay (Hodel et
al., 1997), also showed wild-type levels of EMSA complex
formation (Fig. 5C). Next, capped and uncapped versions of
a longer RNA substrate, G(A)20U, were synthesized and
tested as competitors for VP39-capped 5mer RNA interac-
tion (Fig. 5D). At 50- to 150-fold molar excess over the
labeled probe, both the capped and the uncapped versions
of the longer RNA were effective competitors. This experi-
ment indicated that the stability conferred to the VP39–5mer
RNA interaction by the cap (Figs. 5A and 5B) may be
insufficient to resist competition by larger amounts of a
longer uncapped RNA (Fig. 5D). Thus, both the cap and an
associated RNA chain of ;5 nt appear to contribute to
VP39 binding stability.
Evidence that VP39 possesses two independent RNA
binding sites
To further investigate the effects of cap and chain
length on VP39 binding, kinase-labeled and cap-labeled
FIG. 5. Cap-dependent VP39–RNA interaction assayed by EMSA. (A) EMSA gel showing the absence of complexes with an uncapped 5-nt RNA
32PG(A)4. 2, 1 represent RNA incubations in the absence and presence, respectively, of VP39-DC26. (B) EMSA gel showing that VP39-DC26 forms
a diffuse complex with a 32P cap-labeled version of the 5-nt RNA, m7GpppG(A)4. For both left and right panels, 2 represents an RNA sample without
added protein, the remaining assays contained VP39-DC26. 0 represents no competitor, 7, 20, and 70 represent fold molar excess of unlabeled
competitor over cap-labeled m7GpppG(A)4 probe (2 pmol of the latter being present in each assay). (Left) Uncapped 5mer RNA competitor, pppG(A)4.
(Right) Capped 5mer RNA competitor (m7GpppG(A)4). (C) EMSA of VP39-DC26 mutants lacking m
7G-contact sidechains in VP39’s m7G-binding pocket
(Hodel et al., 1997). Amounts of protein in the assay were as follows: 4.8 mg (wild-type VP39-DC26, labeled DC26), 3.5 mg (Y22A), 6 mg (F180A), 5 mg
(D182A), 7 mg (E233A), 2 mg (D182A 1 E233A, labeled Double). Other conditions and symbols were as for (B). (D) EMSA gel showing the behavior
of the complex between VP39-DC26 and a 32P m7GpppG(A)4 probe in the presence of large excess amounts of unlabeled, uncapped, and capped
G(A)20U. 2 and 1 are as described in (A). Other conditions and symbols are as for (B).
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versions of the longer G(A)20U RNA were tested as
EMSA probes and competitors (Fig. 6). An initial EMSA
experiment was performed using kinase-labeled G(A)20U
probe (Fig. 6A). In the absence of unlabeled ‘‘competitor’’
RNA (1 lane), a smear was observed migrating more
slowly than the free probe. The low abundance and
FIG. 6. EMSA analysis of the interaction of VP39-DC26 with labeled G(A)20U. The faint horizontal line running across all gels, just above the free (uncomplexed)
labeled G(A)20U RNA (F) is an artifact of electrophoresis. (A) EMSA gel showing the interaction of
32P-labeled uncapped G(A)20U probe with VP39-DC26. F indicates
free (uncomplexed) RNA. D indicates the diffuse complex observed at low RNA:protein stoichiometry. S represents the slow (second) complex observed upon
elevation of RNA:protein stoichiometry by the addition of unlabeled G(A)20U in either uncapped (pppG(A)20U) or capped (m
7GpppG(A)20U) form. 2 and 1 are as in
Fig. 5; 40, 120, and 400 represent fold mass excess of unlabeled over labeled RNA. Each assay contained 130 pmol VP39-DC26 and 2 pmol of 32P-labeled RNA.
(B) EMSA gel showing the interaction of 32P cap-labeled m7GpppG(A)20U probe with VP39-DC26. 2, 1, S, D and F are as in (A). 12, 36, and 120 represent fold mass
excess of unlabeled competitor RNA. A schematic interpretation of the data is shown above the figure, in which represents VP39-DC26, with the two vertical faces
representing the two proposed RNA binding sites. The site on the lefthand face is cap-specific, with a nick at the upper lefthand corner representing the cap-binding
site. represents unlabeled, uncapped G(A)20U, represents unlabeled m
7GpppG(A)20U (with the open diamond representing the unlabeled m
7G cap structure),
represents unlabeled m7GpppG(A)4, and represents
32P cap-labeled m7GpppG(A)20U (with the filled diamond representing the labeled cap structure).
m7GpppG(A)20U depicted with a bend in the stem represents binding of the capped RNA in a cap-independent manner. (C) EMSA gel showing the interaction of
VP39-DC26 with 32P-cap-labeled m7GpppG(A)20U in the presence of unlabeled pppG(A)4 or m
7GpppG(A)4. I represents a slow complex with intermediate mobility.
5, 14, 41, 7, 22, and 43 represent fold mass excess of unlabeled over labeled RNA, other symbols are as described in (A) and (B).
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diffuse nature of the smear indicated dissociation during
electrophoresis, presumably due to an unstable VP39–
probe interaction. Addition of an unlabeled form of the
probe RNA, either uncapped or capped, in 40-fold excess
over the labeled probe (40 lane of Fig. 6A), led to the
formation of a faint second complex with low electro-
phoretic mobility (labeled S). We suggest that the S
complex represents the binding of two RNA molecules to
distinct RNA binding sites of VP39. The requirement for
an increased total amount of RNA in the assay for the S
complex to be observed would result from the large
amounts of VP39 present in the assay with respect to
probe alone. Addition of still greater amounts of the
unlabeled competitor RNA (120 and 400 lanes of Fig. 6A)
led to loss of all complexes, apparently due to true
competition.
The experiment of Fig. 6A was repeated using cap-
labeled G(A)20U as the EMSA probe (Fig. 6B). As with the
uncapped G(A)20U probe (Fig. 6A), a diffuse smear was
observed for VP39 in the presence of probe alone (Fig.
6B 1 lane, labeled D), and inclusion of excess unlabeled,
uncapped G(A)20U competitor along with the capped
probe led to the appearance of an S complex (Fig. 6B, 3rd
lane from left). However, the smear and the S complex
with the capped 22mer probe (Fig. 6B) were consistently
far more abundant, with respect to the uncomplexed
RNA, than were the equivalent complexes observed us-
ing the equivalent uncapped probe (Fig. 6A). Further-
more, in contrast to the situation with uncapped probe
(Fig. 6A), the S complex observed with capped probe
could not be competed by large excess amounts of the
unlabeled, uncapped RNA (Fig. 6B, third–fifth lanes from
left). The increased abundance of complexes with the
capped probe, and their resistance to competition by the
uncapped competitor, suggested a cap-dependent sta-
bilization of VP39–22mer probe interaction equivalent to
that observed using the shorter (5mer) probe (Figs. 5A
and 5B). Taken together, the experiments of Figs. 5, 6A,
and 6B suggested that VP39 possesses distinct cap-
stabilized and cap-independent RNA binding sites, inter-
actions at the former also being stabilized by an in-
creased RNA chain length from 5 to 22 nt. In Fig. 6B (final
three lanes) capped instead of uncapped G(A)20U com-
petitor was used. As with the uncapped competitor, the
lowest concentration of capped competitor titrated the
diffuse complex into the S complex. Since only capped
RNA was present in the assay, both of the RNA mole-
cules bound to VP39 in the S complex would be capped,
providing evidence that the cap-independent binding site
does not exclude segments of RNA chain associated
with capped RNA. Greater excess amounts of capped
competitor led to a loss of the slow complex (Fig. 6B, final
two lanes). This is not surprising, since the capped
G(A)20U competitor, unlike the uncapped version, can
displace its cap-labeled counterpart from the cap-stabi-
lized RNA binding site. The slight increase in amount of
free probe that occurs upon addition of uncapped com-
petitor to the cap-labeled probe (Fig. 6B, third–fifth lanes)
can be explained by the ability of the cap-independent
binding site to bind capped RNA chain (above). Thus, the
capped G(A)20U would bind most stably to the cap-
stabilized site, but would also form a relatively unstable
complex with the cap-independent site. The D band of
Fig. 6B (1 lane) would therefore contain a mixture of
these two complexes (see schematic above the figure).
The uncapped competitor would selectively displace the
capped probe from the cap-independent site, leading to
the reappearance of some free probe (fifth lane from left).
The above interpretation of Fig. 6B was tested by
combining the capped 22mer probe with shorter unla-
beled RNAs (uncapped and capped GA4) to create com-
plexes of distinct mobility (Fig. 6C). Uncapped GA4 did
not significantly affect the smear resulting from VP39-
capped G(A)20U interaction (Fig. 6C, lanes 2–5), consis-
tent with its inability to interact with VP39 (Figs. 5A and
5B). However, when unlabeled, capped GA4 was used, a
distinct, diffuse complex was observed (Fig. 6C, lanes
6–8, labeled I) whose mobility was intermediate between
the mobilities of the diffuse complex and the slow (S)
complex observed in Fig. 6B. Its electrophoretic mobility
suggested that it was equivalent to the S complex of Fig.
6B, but contained unlabeled m7GpppG(A)4 in place of
unlabeled m7GpppG(A)20U. Since stable EMSA complex
formation with the short (GA4-based) RNA is cap-depen-
dent (Fig. 5A), the binding of m7GpppG(A)4 in the I com-
plex of Fig. 6C presumably occurs exclusively at VP39’s
cap-stabilized RNA binding site. Therefore, the cap-la-
beled m7GpppG(A)20U probe in the I complex presum-
ably binds at VP39’s cap-independent RNA binding site.
If this is so, then the I complex should also be observed
using an uncapped (59 P-labeled) G(A)20U probe in com-
bination with unlabeled m7GpppG(A)4. Under these con-
ditions a very diffuse I complex was indeed observed
(data not shown), supporting the above interpretation of
the I complex and thereby our interpretation of the S
complex based upon Fig. 6B.
Substrate molecules whose 39 ends interact with the
VP55-VP39 heterodimer are not strongly favored for
59 cap-specific 29-O-methylation
Since VP39 appears to have two independent RNA
binding sites (Fig. 6), and can also 29-O-methylate the
cap structure while associated with VP55 (Fig. 4), we
wondered whether VP39 might preferentially 29-O-meth-
ylate the cap while engaged in poly(A) tail elongation.
Since heterodimer molecules acting at the RNA 39 end
might be expected to preferentially 29-O-methylate the
capped 59 end of the same RNA molecule due to the
higher local concentration of the latter over the 59 ends of
other RNA molecules, we addressed the issue by assay-
ing for the preferential 29-O-methylation of RNAs under-
going 39 end modification by the heterodimer. The assay
employed cap 0-terminated A50 as a substrate for both
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tail elongation and cap 29-O-methylation. 29-O-methyl-
ation of this substrate in the presence of [3H]AdoMet
would lead to the appearance of labeled product, and
polyadenylation would change the RNA’s electrophoretic
mobility. In a control experiment to determine the activity
of the capped A50 substrate at pH 8.0 (a compromise
between the optimal polyadenylation and methylation pH
values of 9.0 and 7.5, respectively), the substrate was first
[3H]methyl labeled by VP39 (not shown), then subjected
to poly(A) tail elongation by the VP55-VP39 heterodimer
in a timecourse assay (Fig. 7A). In a second experiment,
the substrate was simultaneously 29-O-methylated and
polyadenylated by the heterodimer, in a reaction contain-
ing a ;20-fold molar excess of RNA over the het-
erodimer (Fig. 7B). During the course of the reaction,
tritium appeared to be incorporated into bands corre-
sponding to the polyadenylation substrate and products
at equivalent rates, indicating that RNA molecules whose
39 ends have interacted with the heterodimer (polyade-
nylation products) are not strongly favored for cap-spe-
cific 29-O-methylation.
DISCUSSION
Vaccinia protein VP39 is bifunctional. The aim of this
study was to investigate possible relationships between
the two functions, using biochemical approaches. We
found that substrates for one reaction did not have a
significant effect upon the other. For example, the pres-
ence of an oligo(A) tail (substrate for VP39’s tail elonga-
tory activity) did not significantly affect the rate at which
VP39 could 29-O-methylate a 59 cap 0 structure attached
to the same RNA molecule (Fig. 3). This indicates that the
tail does not play a role in bringing monomeric VP39 into
the proximity of the cap. Although the polyadenylation
cofactor, Mg.ATP, had no effect on cap 29-O-methylation
(Fig. 3), equivalent concentrations of free adenine are
inhibitory (S.W. Lockless and P.D. Gershon, unpublished
data). This is presumably because adenine is more
closely related than ATP to the adenosyl moiety of the
methyltransferase cofactor AdoMet. In additional exper-
iments, the 29-O-methyltransferase substrate (cap 0-ter-
minated RNA), cofactor (AdoMet), and coproduct
(AdoHcy) did not appear to affect poly(A) tail elongation.
One precedent for examining the effect of AdoHcy upon
polyadenylation is the unusual effect of AdoHcy upon
poly(A) tail length in vesicular stomatitis virus (VSV). In
VSV, the multifunctional viral L protein mediates in-
creased poly(A) tail lengths in response to AdoHcy (Hunt
et al., 1988; Hunt and Hutchinson, 1993), presumably as
a consequence of the protein’s roles in both cap and
poly(A) tail formation. Since tail lengths due to the VP55-
VP39 heterodimer did not change significantly in re-
sponse to AdoHcy in vitro (Figs. 1B and 1D), VP39 ap-
parently does not mediate such a coupling through an
interaction between its AdoHcy-binding (Barbosa and
Moss, 1978) and poly(A) tail elongatory (Gershon and
Moss, 1993a) activities. This would be consistent with
the complete dissimilarity of vaccinia virus and VSV in
terms of replication mechanisms, genome structure and
size, and gene expression mechanisms.
One explanation for the absence of detectable sub-
strate cross-modulation could be that VP39’s two func-
tions are mutually exclusive, such that a single VP39
molecule cannot carry out both functions simultaneously.
FIG. 7. Substrate molecules whose 39 ends interact with the VP55-VP39 heterodimer are not strongly favored for 59 cap-specific 29-O-methylation.
(A) Polyadenylation timecourse assay, in which the polyadenylation substrate comprised ;20 pmol of cap I-terminated A50 RNA possessing a
3H-labeled 29-O-methyl group. The polyadenylation reaction contained ;1 pmol each of VP55 and VP39. Numbers are time (min) at which samples
were taken. (B) Simultaneous 29-O-methylation and poly(A) tail elongation of ;20 pmol of cap 0-terminated A50, in which the transferred methyl group
is 3H labeled. M denotes a separate 29-O-methylation reaction in the absence of polyadenylation (i.e., ATP omitted from the reaction). Experimental
details are given under Materials and Methods; other details are given in the legend to (A).
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Since VP39 is able to modify RNA 39 ends only in the
context of the VP39-VP55 heterodimer, heterodimeriza-
tion would provide a simple and attractive mechanism to
switch VP39 from 59 to 39 end modifying functions. Al-
though an earlier experiment (Fig. 2 of Schnierle et al.,
1992) indicated the heterodimer to be active in cap-
specific 29-O-methylation in vitro, the previous experi-
ment also suggested the heterodimer to be slightly less
active than free VP39. Moreover, the heterodimer con-
centrations used previously (,;1028 M) were compara-
ble to the Kd for heterodimer dissociation to monomeric
subunits (P. D. Gershon, unpublished data), raising ques-
tions about the heterodimer’s association status in the
experiment. The experiments of Fig. 4 employed higher
protein concentrations, multiple datapoints per assay,
and a dimerization-defective mutant as a negative con-
trol. Furthermore, replicate experiments at still higher
protein concentrations (data not shown) also showed
dimerization to have no detectable effect upon 29-O-
methyltransferase activity. We therefore conclude that
association with VP55 does not switch the function of
VP39. An alternative explanation for the apparent ab-
sence of cross-modulation between VP39’s two functions
might be that they employ completely independent, non-
interfering domains of the protein. This would require
two separate RNA binding sites for VP39’s two activities.
In an attempt to detect more than one RNA binding site,
an EMSA was developed. The complexes observed in
the absence of unlabeled competitor RNA were diffuse,
indicating the occurrence of equilibrium dissociation
during electrophoresis. This may have been encouraged
by VP39’s pI of ;8.3 (Barbosa and Moss, 1978), close to
the pH of the electrophoresis buffer. High protein con-
centrations (10 mM) were required for any EMSA com-
plexes to be observed at all, indicating that dissociation
could be retarded through mass action. Consistent with
this, additional increases in protein concentration be-
yond those used here led to further retardation of the
average electrophoretic mobility of the diffuse com-
plexes (data not shown). Despite the above factors, sur-
prisingly reproducible data were obtained in the EMSA.
Cap-dependent (Fig. 5) and cap-enhanced (Fig. 6) com-
plex formation were observed, consistent with the re-
sults of previous studies using the BIAcore instrument
(Shi et al., 1996), in which VP39–RNA complexes exhib-
ited a cap-dependent enhancement in binding stability.
The observation of a slow second complex in EMSAs
when using longer (22mer) RNA probes under conditions
of elevated RNA:protein stoichiometry indicated the oc-
currence of two distinct RNA binding sites per VP39
molecule. This latter observation contrasts with the be-
havior of VP55 in the EMSA, in which slow complexes
arise under the converse conditions (elevated protein:
RNA stoichiometry), due to the presence of multiple
protein binding sites per RNA molecule (e.g., Fig. 2B
(Gershon and Moss, 1993b)). Other data (not shown), in
which experiments similar to those of Figs. 6A and 6B
were performed using 50-nt in place of 20-nt RNAs, also
showed the binding of two RNAs per VP39 molecule.
This indicated that VP39’s two RNA binding sites are not
parts of a single, much larger RNA binding domain that
can be bridged by a single 50mer RNA.
Whereas unlabeled G(A)20U was able to titrate cap-
labeled m7GpppG(A)20U into a slow EMSA complex
(Fig. 6B), it displaced cap-labeled m7GpppG(A)4 from
the protein entirely (Fig. 5D). This would indicate that
VP39 interacts with the longer capped RNA more
strongly than with the capped 5mer. Consistent with
this, VP39’s KM for 29-O-methylation of m
7GpppG(A)20U
is significantly lower than for 29-O-methylation of
m7GpppG(A)4 (Lockless et al., 1998). VP39 possesses
a cleft adjacent to its m7G binding pocket, which
passes though the 29-O-methyltransferase catalytic
center and accommodates the first three transcribed
nucleotides of the RNA chain (Hodel et al., 1996, 1997,
1998). The functional data shown here are consistent
with the conclusion of a sister study (Lockless et al.,
1998) that an RNA binding site located beyond the cleft
plays a role in VP39’s 29-O-methyltransferase function.
Under in vitro polyadenylation conditions, the act of
polyadenylation by the heterodimer had little or no
effect on its 29-O-methyltransferase activity and did not
promote selective cap-specific 29-O-methylation of the
RNA molecule undergoing polyadenylation (as op-
posed to other RNA molecules; Fig. 7). Indeed, RNA
molecules undergoing tail elongation appeared to be
neither preferred nor disadvantaged for cap-specific
29-O-methylation. Thus, there is no evidence to sug-
gest the occurrence of polyadenylation-dependent cap
29-O-methylation, as has recently been detected for
certain Xenopus cytoplasmic mRNAs in ovo (Kuge and
Richter, 1995). Since heterodimer molecules partici-
pating in RNA 39 end modification might be expected
to experience an elevated local concentration of RNA
59 ends, it is not clear why RNA molecules undergoing
tail elongation did not experience some degree of
preferential 29-O-methylation. One explanation might
be that the VP55-VP39-poly(A) ternary complex lacks
29-O-methyltransferase activity.
In summary, the evidence presented herein suggests
that VP39’s two functions act independently of one an-
other, via independent RNA binding sites on the protein
surface.
MATERIALS AND METHODS
Materials
The vaccinia-expressed VP55 and VP39 used here
have been described previously (Gershon and Moss,
1992, 1993a). For some experiments (e.g., Fig. 4) baculo-
virus-expressed VP55 (Shi et al., 1997) was employed.
Escherichia coli-expressed VP39 was generated as de-
scribed previously (Gershon and Moss, 1996; Shi et al.,
1996). Very high purity VP39-DC26 (a 26-amino-acid C-
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terminal truncation mutant of VP39 (Schnierle et al.,
1994)) was expressed in E. coli and purified as described
previously (Gershon and Moss, 1996; Hodel et al., 1996).
The final column (heparin–agarose) yielded highly puri-
fied protein at a concentration of 4.8 mg/ml, which was
used for the experiments described herein as well as for
crystallographic studies (Hodel et al., 1997). The gener-
ation, expression, and purification of the VP39 point mu-
tant proteins used for the experiment shown in Fig. 5C
have been described (Hodel et al., 1997; Lockless et al.,
1998). After heparin–agarose column chromatography,
and before use, each of the mutant proteins was con-
centrated by ultrafiltration (Centricon, Amicon) to 3.5
mg/ml (Y22A), 6 mg/ml (F180A), 5 mg/ml (D182A), 7
mg/ml (E233A), and 2 mg/ml (D182A 1 E233A). Vaccinia
virus capping enzyme was purified from soluble virion
extract by passage through two diethylaminoethyl (DE-
AE)–cellulose columns, followed by binding and salt-
gradient elution from sequential columns of single-
stranded DNA–agarose and heparin–agarose. The final
preparation appeared by electrophoresis to be free of
VP39, though small amounts of capped RNAs generated
by the capping enzyme preparation (up to 25%) were
found, by C18 column chromatography (Lockless et al.,
1998; data not shown) to be in the cap I form. This
indicated the presence of trace amounts of contaminat-
ing VP39.
Triphosphate-terminated VGF 60mer RNA was synthe-
sized enzymatically, as described previously (Gershon
and Moss, 1993a). Triphosphate- and cap 0-terminated
G(A)n and -G(A)nU transcripts were synthesized enzymat-
ically, using T7 RNA polymerase, as described (Lockless
et al., 1998; Milligan and Uhlenbeck, 1989). For RNA
synthesized using m7GpppG cap analog (unlabeled,
capped RNA), 30–50% of transcripts would be expected
to possess cap dinucleotide incorporated in the forward
(m7GpppG(N)n) as opposed to the reverse (Gpppm
7G(N)n)
direction (Pasquinelli et al., 1995). Transcripts possess-
ing oligo(A) tracts were generally somewhat heteroge-
neous in length, typically varying between the target size
and a size corresponding to ;five additional adenylates.
Where necessary, individual uncapped and forward-
capped RNA species were purified from the mixtures of
transcription products generated when using short tem-
plates (i.e., those with 5-nt transcribed regions), by using
C18 column chromatography (Lockless et al., 1998).
RNA 59 end modification
Labeled, monophosphate-terminated RNA was gener-
ated by dephosphorylation of enzymatically synthesized,
triphosphate-terminated RNA (above), followed by re-
phosphorylation using phage T4 polynucleotide kinase
and [g-32P]ATP (Gershon and Moss, 1993a). Some of the
resulting 59 end-labeled RNAs (e.g., G(A)4) were subse-
quently purified by denaturing PAGE. Triphosphate-termi-
nated RNAs were modified to the cap 0 form using the
vaccinia capping enzyme (Materials, above). For the ad-
dition of unlabeled cap, reactions contained 50 mM Tris–
HCl, pH 7.5; 50 mM DTT; 12.5 mM MgCl2; 0.5 mM S-
adenosyl-L-methionine; 20 U RNAsin (Promega); 1 mM
GTP; 59 triphosphate-terminated RNA; and 2 ml of vac-
cinia capping enzyme, in a total volume of 20 ml. Reac-
tions were incubated for 2 h at 37°C. Conditions for the
generation of 32P- or 3H-labeled (at the m7G position) cap
0 were identical except for the replacement of unlabeled
GTP or AdoMet with either [a-32P]GTP (20 mCi) or
[3H]AdoMet (1.1 mCi; 11 Ci/mMol; DuPont NEN), respec-
tively. The proportion of RNAs which became capped
was not determined. Unlabeled and 3H-containing cap-
ping reactions were terminated by supplementing with
40 ml of RNase-free water, then extracting with an equal
volume of phenol/chloroform, followed by chloroform
alone. Following extraction, aqueous phases were ex-
changed into an equivalent volume (60 ml) of RNase-free
water using a Bio-spin 6 column (Bio-Rad). 32P cap-
labeled RNA was supplemented with an equal volume
(20 ml) of formamide and purified from a 20% polyacryl-
amide/TBE/urea gel. This would ensure the removal of
unlabeled AdoMet from the cap-labeling reaction. For the
experiment shown in Fig. 7A, enzymatically synthesized
cap 0-terminated G(A)50U RNA (Materials, above) was
converted to the 3H cap I-form using VP39 (0.4 mg) and
[3H]AdoMet (13.75 mCi; 55 Ci/mMol) in 25 mM Tris–HCl,
pH 8.0, 1 mM DTT, for 60 min at 30°C. It was then
extracted with phenol/chloroform, followed by chloroform
alone. Following extraction, the aqueous phase was ex-
changed into an equivalent volume of 25 mM Tris–HCl,
pH 8.0, 1 mM DTT using a Bio-spin 6 column. The volume
of the resulting material was reduced ;two-fold under
vacuum before use in the polyadenylation timecourse
assay (below).
39-Oligoadenylation of unlabeled, 59-cap 0-modified
VGF 60mer RNA
For the experiment shown in Fig. 3A, VGF 60mer RNA
whose 59 end had been modified to unlabeled cap 0
followed by exchange into RNase-free water (previous
section) was divided into two equal portions. One portion
was incubated with VP55 (50 ng) in a buffer comprising
1.25 mM MgCl2, 1.25 mM ATP, 62.5 mM Tris–HCl (pH 9.0),
6.25 mM DTT, in a total volume of 40 ml. Following a
10-min incubation at 37°C, the reaction was extracted
once with phenol/chloroform, then once with chloroform
alone. The resulting aqueous phase was mixed with the
portion of cap 0-modified RNA that had not been sub-
jected to polyadenylation, and the RNA mixture ex-
changed into RNase-free water by spin-gel filtration as
described above.
29-O-methyltransferase and polyadenylation assays
The standard cap-specific 29-O-methyltransferase
assay, using Brome mosaic virus RNA as a substrate
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and DEAE filter binding for [3H]RNA product isolation
(Fig. 3B), was performed as described previously (Shi
et al., 1996). For the methyltransferase electrophoretic
timecourse assay shown in Fig. 3A, the desalted RNA
mixture described in the previous section (70 ml) was
supplemented with 25 mM N-[2-hydroxyethyl]pipera-
zine-N9-[2-ethanesulfonic acid] (HEPES)-NaOH (pH
7.5), 1 mM DTT, and [3H]AdoMet (3.3 mCi; 11 Ci/mmol)
in a total reaction volume of 90 ml. E. coli-expressed
VP39 was then added, and 9-ml samples were taken
after various times and mixed with 6-ml aliquots of
formamide. After heating for 2 min at 95°C, 12-ml
portions of the RNA samples were loaded on an 8%
polyacrylamide/urea/TBE gel. Reaction conditions for
the experiment shown in Fig. 4 were similar except for
(i) the use of 29-O-methylation substrate comprising
unpurified products from an m7GpppG-initiated, G(A)5-
templated T7 transcription reaction; (ii) the inclusion of
baculovirus-expressed VP55 in some reactions in
2.75-fold molar excess over 2.74 pmol E. coli-ex-
pressed VP39 or point mutant CF3c2 (Shi et al., 1997);
and (iii) the omission of a heat pulse immediately prior
to electrophoresis. After electrophoresis, methyltrans-
ferase timecourse gels were soaked in 30% metha-
nol/5% acetic acid (30 min), then in either Entensify
(NEN) or Fluoro-Hance (RPI) following the manufactur-
ers’ directions. After drying, gels were exposed to
preflashed X-ray film at 270°C.
The standard polyadenylation timecourse assay (Figs.
1 and 2) was conducted as described previously (Ger-
shon and Moss, 1993a). A similar protocol was employed
for the polyadenylation timecourse experiments using
3H-labeled RNA (Figs. 2B and 7A). However, the polyad-
enylation timecourse assay shown in Fig. 7A differed
from others in that equimolar amounts of vaccinia-ex-
pressed VP55 and VP39 (;50 ng of each) were used,
instead of the standard excess amount of VP39, and in
the replacement of 50 mM Tris–HCl, pH 9.0, in the assay
buffer with 25 mM Tris–HCl, pH 8.0. For the simultaneous
29-O-methylation and polyadenylation timecourse reac-
tion shown in Fig. 7B, ;20 pmol of RNA substrate was
incubated with 25 mM Tris–HCl, pH 8.0, 1 mM DTT,
[3H]AdoMet (27.5 mCi; 55 Ci/mmol) and 1 mM Mg.ATP at
30°C for 5 min, before initiating the reactions by com-
bining the above mixture with vaccinia-expressed VP55
and VP39 (;1 pmol of each). For the experiments shown
in Fig. 7, timepoint samples were mixed with equal
amounts of formamide and electrophoresed in 8% poly-
acrylamide, 7 M urea, TBE-buffered gels which were
fluorographed as described above.
EMSA
RNA samples were cap-labeled or kinase-labeled with
32P, as described above, then purified from 20% poly-
acrylamide gels. Labeled and unlabeled RNA samples
were mixed in methyltransferase assay buffer (above)
supplemented with 10% glycerol, then 14-ml aliquots of
the buffered RNA mixture were supplemented with
4.8-mg aliquots of very high purity E. coli-expressed
VP39-DC26 or mutants thereof (described above). After
incubation at room temperature for ;5 min, samples
were electrophoresed in 10 or 12% polyacrylamide, 0.53
TBE (pH 8.3) gels, at 160 V (max)/20 mA (max). Dried gels
were imaged using a PhosphorImager (Molecular Dy-
namics).
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